The medtech giant’s Diabetes business unit — set to become a standalone public company called MiniMed through an IPO — said it struck agreements with major pharmacy benefit managers (PBMs) and PBM group purchasing organizations (GPOs), including Ascent and Zinc.
According to Medtronic, the agreements include access to its expanded CGM portfolio, including its own Simplera and Simplera Sync sensors, plus the recently launched Instinct sensor, made by Abbott. It builds on existing pharmacy coverage for Medtronic CGMs and consumables like infusion sets and reservoirs.
The Medtronic Diabetes Business is one of the largest diabetes tech companies in the world — learn more about the company and the rest of the diabetes space by downloading our free Diabetes Technology Special Report.
Medtronic said its dedicated MiniMed payer account team continues to collaborate with downstream health plans partnered with the PBMs. It hopes to expand coverage of the MiniMed 780G system under the pharmacy benefit. The company says its access gains strengthen its end-to-end access to its technologies through the pharmacy channel.
To support a streamlined experience providers can continue to prescribe the MiniMed 780G system. The company intends to continue to manage benefit investigation across both pharmacy and durable medical equipment (DME) options.
“Expanding pharmacy benefit coverage for the MiniMed™ 780G system is an important step forward in how people access automated insulin delivery,” said Que Dallara, EVP & President of Medtronic Diabetes. “Access through the pharmacy channel can help lower upfront costs compared to traditional durable medical equipment (DME) pathways and make it easier for people to get started on therapy. It also allows patients and care teams to better align pumps, sensors, and consumables under a single coverage pathway, supporting greater predictability when navigating access.”
